Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Antigenics Will Collect Survival Data Before Taking Next Steps With Oncophage Vaccine

This article was originally published in The Pink Sheet Daily

Executive Summary

Antigenics will work with FDA to determine an appropriate path to market for the kidney cancer vaccine, but the firm says it would need a partner if another trial is needed.

You may also be interested in...



Antigenics’ Oncophage Cancer Vaccine Enters Phase II Glioma Study

Brain cancer trial co-sponsored by NCI follows Phase I/II investigator-sponsored study in which a tumor-specific immune response was detected in all 12 patients.

Antigenics’ Oncophage Cancer Vaccine Enters Phase II Glioma Study

Brain cancer trial co-sponsored by NCI follows Phase I/II investigator-sponsored study in which a tumor-specific immune response was detected in all 12 patients.

Genitope Maintains Positive View On MyVax Despite DSMB Interim Review

Data safety monitoring board recommends Genitope continue a Phase III trial of the cancer vaccine, suggesting more data is needed.

Related Content

Topics

UsernamePublicRestriction

Register

ID1122310

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel